AWA
BCYC

Arete Wealth Advisors’s Bicycle Therapeutics BCYC Stock Holding History

Arete Wealth Advisors’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,772
Closed -$227K – 414
2023
Q4 		$227K Buy
+3,772
New +$62.4K 0.02% 633

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Arete Wealth Advisors's BCYC Position: Q1 2024 in Review

Arete Wealth Advisors sold out of Bicycle Therapeutics (BCYC) in Q1 2024, closing a stake of 3,772 shares — an estimated $227K sold.

Arete Wealth Advisors first reported a position in BCYC in Q4 2023 and held it in 1 quarter. The position peaked at $227K in Q4 2023. 95 funds tracked by Wall St. Rank hold BCYC as of Q1 2024.

  • Arete Wealth Advisors reported no remaining Bicycle Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Arete Wealth Advisors sold 3,772 Bicycle Therapeutics shares in Q1 2024, an estimated $227K.
  • Arete Wealth Advisors first reported a position in Bicycle Therapeutics in Q4 2023 and held it in 1 quarter.
  • Arete Wealth Advisors's Bicycle Therapeutics position peaked at $227K in Q4 2023.
  • 95 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2024.

Based on Arete Wealth Advisors's 13F filing for Q1 2024, filed 16 May 2024.